

# Marco Petrillo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7327245/publications.pdf>

Version: 2024-02-01

88  
papers

2,376  
citations

159358

30  
h-index

243296

44  
g-index

88  
all docs

88  
docs citations

88  
times ranked

3696  
citing authors

#	ARTICLE	IF	CITATIONS
1	Quality of life and emotional distress in early stage and locally advanced cervical cancer patients: A prospective, longitudinal study. <i>Gynecologic Oncology</i> , 2012, 124, 389-394.	0.6	113
2	Targeting CD133 antigen in cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2009, 13, 823-837.	1.5	95
3	Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: A case-control study on survival in patients with two year follow-up. <i>Gynecologic Oncology</i> , 2012, 127, 502-505.	0.6	91
4	CD133 antigen expression in ovarian cancer. <i>BMC Cancer</i> , 2009, 9, 221.	1.1	77
5	Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts. <i>Cancer Letters</i> , 2017, 388, 320-327.	3.2	73
6	Polarisation of Tumor-Associated Macrophages toward M2 Phenotype Correlates with Poor Response to Chemoradiation and Reduced Survival in Patients with Locally Advanced Cervical Cancer. <i>PLoS ONE</i> , 2015, 10, e0136654.	1.1	70
7	Sox9 and Hif-2 $\beta$ regulate TUBB3 gene expression and affect ovarian cancer aggressiveness. <i>Gene</i> , 2014, 542, 173-181.	1.0	65
8	BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 217, 334.e1-334.e9.	0.7	65
9	Quality of life and psychological distress in locally advanced cervical cancer patients administered pre-operative chemoradiotherapy. <i>Gynecologic Oncology</i> , 2008, 111, 144-150.	0.6	62
10	Long-term prospective longitudinal evaluation of emotional distress and quality of life in cervical cancer patients who remained disease-free 2-years from diagnosis. <i>BMC Cancer</i> , 2013, 13, 127.	1.1	61
11	Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2014, 211, 632.e1-632.e8.	0.7	60
12	Role and prognostic significance of the epithelial-mesenchymal transition factor ZEB2 in ovarian cancer. <i>Oncotarget</i> , 2015, 6, 18966-18979.	0.8	57
13	Expression of nucleoside transporters, deoxycytidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 679-686.	1.1	56
14	Evaluation of quality of life and emotional distress in endometrial cancer patients: A 2-year prospective, longitudinal study. <i>Gynecologic Oncology</i> , 2014, 133, 518-525.	0.6	56
15	Prognostic significance of the estrogen receptor beta (ER $\beta$ ) isoforms ER $\beta$ 1, ER $\beta$ 2, and ER $\beta$ 5 in advanced serous ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 132, 351-359.	0.6	55
16	Recurrence rate after loop electrosurgical excision procedure (LEEP) and laser Conization: A 5-year follow-up study. <i>Gynecologic Oncology</i> , 2020, 159, 636-641.	0.6	54
17	Minimally Invasive Secondary Cytoreduction Plus HIPEC Versus Open Surgery Plus HIPEC in Isolated Relapse From Ovarian Cancer: A Retrospective Cohort Study on Perioperative Outcomes. <i>Journal of Minimally Invasive Gynecology</i> , 2015, 22, 428-432.	0.3	52
18	Neoadjuvant Chemotherapy Followed by Maintenance Therapy With or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control Study. <i>Annals of Surgical Oncology</i> , 2015, 22, 952-958.	0.7	51

#	ARTICLE	IF	CITATIONS
19	Robotic Versus Laparoscopic Staging for Early Ovarian Cancer: A Case-Matched Control Study. <i>Journal of Minimally Invasive Gynecology</i> , 2017, 24, 293-298.	0.3	45
20	Quality of Life in Women After Pelvic Exenteration for Gynecological Malignancies. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 267-273.	1.2	45
21	Selective Changes in the Immune Profile of Tumor-Draining Lymph Nodes After Different Neoadjuvant Chemoradiation Regimens for Locally Advanced Cervical Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 1546-1553.	0.4	42
22	Epithelial ovarian cancer relapsing as isolated lymph node disease: natural history and clinical outcome. <i>BMC Cancer</i> , 2008, 8, 367.	1.1	41
23	Influence of Intraperitoneal Dissemination Assessed by Laparoscopy on Prognosis of Advanced Ovarian Cancer: An Exploratory Analysis of a Single-Institution Experience. <i>Annals of Surgical Oncology</i> , 2014, 21, 3970-3977.	0.7	41
24	Laparoscopic Versus Laparotomic Surgical Staging for Early-Stage Ovarian Cancer: A Case-Control Study. <i>Journal of Minimally Invasive Gynecology</i> , 2016, 23, 769-774.	0.3	38
25	Adjuvant HPV Vaccination to Prevent Recurrent Cervical Dysplasia after Surgical Treatment: A Meta-Analysis. <i>Vaccines</i> , 2021, 9, 410.	2.1	38
26	Novel targets for VEGF-independent anti-angiogenic drugs. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 451-472.	1.9	36
27	Can radicality of surgery be safely modulated on the basis of MRI and PET/CT imaging in locally advanced cervical cancer patients administered preoperative treatment?. <i>Cancer</i> , 2012, 118, 392-403.	2.0	36
28	Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 465, 193-198.	1.4	35
29	High-risk HPV-positive and -negative high-grade cervical dysplasia: Analysis of 5-year outcomes. <i>Gynecologic Oncology</i> , 2021, 161, 173-178.	0.6	34
30	Recurrence in skeletal muscle from squamous cell carcinoma of the uterine cervix: a case report and review of the literature. <i>BMC Cancer</i> , 2006, 6, 169.	1.1	33
31	Role of Extracellular Vesicles in Epithelial Ovarian Cancer: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8762.	1.8	31
32	Clinical impact on ovarian cancer patients of massive parallel sequencing for BRCA mutation detection: the experience at Gemelli hospital and a literature review. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 1383-1403.	1.5	30
33	Assessing the Long-Term Role of Vaccination against HPV after Loop Electrosurgical Excision Procedure (LEEP): A Propensity-Score Matched Comparison. <i>Vaccines</i> , 2020, 8, 717.	2.1	28
34	Efficacy of HPV Vaccination in Women Receiving LEEP for Cervical Dysplasia: A Single Institution's Experience. <i>Vaccines</i> , 2020, 8, 45.	2.1	27
35	Development of a Nomogram Predicting the Risk of Persistence/Recurrence of Cervical Dysplasia. <i>Vaccines</i> , 2022, 10, 579.	2.1	27
36	Uncovering the role of nuclear Lysyl oxidase (LOX) in advanced high grade serous ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 146, 170-178.	0.6	26

#	ARTICLE	IF	CITATIONS
37	Identification and antitumor activity of a novel inhibitor of the NIMA-related kinase NEK6. <i>Scientific Reports</i> , 2018, 8, 16047.	1.6	26
38	Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e59.	1.0	25
39	The impact of COVID-19 lockdown on admission to gynecological emergency departments: Results from a multicenter Italian study. <i>International Journal of Gynecology and Obstetrics</i> , 2020, 151, 39-42.	1.0	23
40	Positron Emission Tomography- Laparoscopy Based Method in the Prediction of Complete Cytoreduction in Platinum-Sensitive Recurrent Ovarian Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 649-654.	0.7	22
41	Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers. <i>Cell Reports</i> , 2016, 17, 1621-1631.	2.9	21
42	Hospital costs incurred by the Italian National Health Service for invasive cervical cancer. <i>Gynecologic Oncology</i> , 2010, 119, 243-249.	0.6	19
43	Ovarian low and high grade serous carcinomas: hidden divergent features in the tumor microenvironment. <i>Oncotarget</i> , 2016, 7, 68033-68043.	0.8	19
44	Expression and subcellular localization of CRH and its receptors in human endometrial cancer. <i>Molecular and Cellular Endocrinology</i> , 2009, 305, 6-11.	1.6	18
45	Prognostic role of the recepteur d'origine nantais (RON) expression in ovarian cancer patients. <i>Gynecologic Oncology</i> , 2008, 111, 237-243.	0.6	17
46	Prognostic role of Ca125 response criteria and RECIST criteria: Analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2008, 109, 187-193.	0.6	16
47	A combined ANXA2-NDRG1-STAT1 gene signature predicts response to chemoradiotherapy in cervical cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 279.	3.5	16
48	Materno-Fetal and Neonatal Complications of Diabetes in Pregnancy: A Retrospective Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 2707.	1.0	16
49	FOXL2 molecular status in adult granulosa cell tumors of the ovary: A study of primary and metastatic cases. <i>Oncology Letters</i> , 2016, 12, 1159-1163.	0.8	15
50	Robotic Total Mesometrial Resection versus Laparoscopic Total Mesometrial Resection in Early Cervical Cancer: A Case-Control Study. <i>Journal of Minimally Invasive Gynecology</i> , 2016, 23, 804-809.	0.3	15
51	Correlation of Leptin, Proinflammatory Cytokines and Oxidative Stress with Tumor Size and Disease Stage of Endometrioid (Type I) Endometrial Cancer and Review of the Underlying Mechanisms. <i>Cancers</i> , 2022, 14, 268.	1.7	14
52	Time Trade-Off Procedure for Measuring Health Utilities Loss With Human Papillomavirus-Induced Diseases: A Multicenter, Retrospective, Observational Pilot Study in Italy. <i>Clinical Therapeutics</i> , 2011, 33, 1084-1095.e4.	1.1	13
53	Secondary malignancies of the uterine cervix: a potential diagnostic pitfall. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 463, 23-29.	1.4	13
54	Completion surgery after concomitant chemoradiation in obese women with locally advanced cervical cancer: Evaluation of toxicity and outcome measures. <i>Acta Oncologica</i> , 2013, 52, 166-173.	0.8	12

#	ARTICLE	IF	CITATIONS
55	Nek6 and Hif-1 $\alpha$ cooperate with the cytoskeletal gateway of drug resistance to drive outcome in serous ovarian cancer. <i>American Journal of Cancer Research</i> , 2015, 5, 1862-77.	1.4	12
56	Comparison of perioperative outcomes between standard laparoscopic and robot-assisted approach in patients with rectosigmoid endometriosis. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2021, 100, 1740-1746.	1.3	11
57	Characteristics and patterns of care of endometrial cancer before and during COVID-19 pandemic. <i>Journal of Gynecologic Oncology</i> , 2022, 33, e10.	1.0	11
58	Conservatively treated glassy cell carcinoma of the cervix. <i>World Journal of Surgical Oncology</i> , 2008, 6, 92.	0.8	10
59	Laparoscopic En Bloc Right Diaphragmatic Peritonectomy for Diaphragmatic Endometriosis According to the Sugarbaker Technique. <i>Journal of Minimally Invasive Gynecology</i> , 2016, 23, 198-205.	0.3	10
60	Systematic Review of Cytoreductive Surgery and Bevacizumab-Containing Chemotherapy in Advanced Ovarian Cancer: Focus on Safety. <i>Annals of Surgical Oncology</i> , 2018, 25, 247-254.	0.7	10
61	The relevance of prelamin A and RAD51 as molecular biomarkers in cervical cancer. <i>Oncotarget</i> , 2017, 8, 94247-94258.	0.8	10
62	A case of drug resistant clear cell ovarian cancer showing responsiveness to gemcitabine at first administration and at re-challenge. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 60, 459-461.	1.1	9
63	Colonic Carcinoma Metastatic to the Endometrium. <i>International Journal of Surgical Pathology</i> , 2011, 19, 787-790.	0.4	9
64	Standardized training programmes for advanced laparoscopic gynaecological surgery. <i>Current Opinion in Obstetrics and Gynecology</i> , 2013, 25, 327-331.	0.9	9
65	Does the diagnosis center influence the prognosis of ovarian cancer patients submitted to neoadjuvant chemotherapy?. <i>Anticancer Research</i> , 2015, 35, 3027-32.	0.5	9
66	Glassy cell carcinoma of the endometrium: A case report and review of the literature. <i>Pathology Research and Practice</i> , 2007, 203, 217-220.	1.0	8
67	The role of surgery in platinum-resistant ovarian cancer: A call to the scientific community. <i>Seminars in Cancer Biology</i> , 2021, 77, 194-202.	4.3	8
68	Vulvar squamous cell carcinoma with sarcoma-like stroma: A case report and review of the literature. <i>Diagnostic Pathology</i> , 2011, 6, 95.	0.9	7
69	Cytoreductive Surgery Plus Platinum-Based Hyperthermic Intraperitoneal Chemotherapy in Epithelial Ovarian Cancer: A Promising Integrated Approach to Improve Locoregional Control. <i>Oncologist</i> , 2016, 21, 532-534.	1.9	7
70	Self-Reported Long-Term Autonomic Function After Laparoscopic Total Mesometrial Resection for Early-Stage Cervical Cancer: A Multicentric Study. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1501-1507.	1.2	7
71	Secondary cytoreduction in ovarian cancer: who really benefits?. <i>Archives of Gynecology and Obstetrics</i> , 2018, 298, 873-879.	0.8	7
72	High Incidence of Gestational Trophoblastic Disease in a Third-Level University-Hospital, Italy: A Retrospective Cohort Study. <i>Frontiers in Oncology</i> , 2021, 11, 684700.	1.3	7

#	ARTICLE	IF	CITATIONS
73	Novel VEGF-independent Strategies Targeting Tumor Vasculature: Clinical Aspects. <i>Current Pharmaceutical Design</i> , 2012, 18, 2702-2712.	0.9	7
74	Prevalence of HPV Infection and p16INK4a Overexpression in Surgically Treated Laryngeal Squamous Cell Carcinoma. <i>Vaccines</i> , 2022, 10, 204.	2.1	7
75	Non-catalytic region of tyrosine kinase adaptor protein 2 (NCK2) pathways as factor promoting aggressiveness in ovarian cancer. <i>International Journal of Biological Markers</i> , 2018, 33, 124-131.	0.7	6
76	The safety of bevacizumab for the treatment of ovarian cancer. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 1107-1113.	1.0	5
77	Is frozen section analysis of pelvic lymph nodes accurate in locally advanced cervical cancer patients administered preoperative chemoradiation?. <i>Gynecologic Oncology</i> , 2008, 108, 220-225.	0.6	4
78	Sentinel Lymph Node Biopsy in Surgical Staging for High-Risk Groups of Endometrial Carcinoma Patients. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 3716.	1.2	4
79	Feasibility and safety of laparoscopic approach in obese patients with endometriosis: a multivariable regression analysis. <i>Archives of Gynecology and Obstetrics</i> , 2020, 302, 665-670.	0.8	3
80	Laparoscopic splenectomy both for primary cytoreductive surgery for advanced ovarian cancer and for secondary surgery for isolated spleen recurrence: feasibility and technique. <i>BMC Surgery</i> , 2021, 21, 380.	0.6	3
81	Survivin protein as predictor of pathologic response in patients with locally advanced cervical cancer treated with chemoradiation followed by radical surgery. <i>Human Pathology</i> , 2014, 45, 1872-1878.	1.1	2
82	Challenges in Gynecological Cancer: Biology, Diagnosis, Surgical, and Medical Treatment. <i>BioMed Research International</i> , 2015, 2015, 1-2.	0.9	2
83	Peritoneal sarcomatosis 5 years after laparoscopic morcellation of uterine leiomyoma. <i>American Journal of Obstetrics and Gynecology</i> , 2018, 218, 626.	0.7	2
84	Pathologic response to neoadjuvant chemotherapy in advanced ovarian cancer: utility of a scoring system to predict outcomes. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1064-1071.	1.2	2
85	A case of isolated ovarian recurrence from vulvar carcinoma. <i>Archives of Gynecology and Obstetrics</i> , 2008, 278, 393-396.	0.8	1
86	Primary extranodal vaginal non-hodgkin lymphoma: Diagnostic pitfalls and therapeutic challenges. <i>Histology and Histopathology</i> , 2019, 34, 723-730.	0.5	1
87	ASO Author Reflections: Surgery and Bevacizumab in Ovarian Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 886-887.	0.7	0
88	Discovery of a Selective NEK6 Kinase Inhibitor by Virtual Screening. <i>Proceedings (mdpi)</i> , 2019, 22, 21.	0.2	0